Trial Profile
A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms MAM
- 05 Nov 2020 Status changed from active, no longer recruiting to completed.
- 03 Jul 2019 Planned End Date changed from 31 Oct 2019 to 31 Dec 2019.
- 30 Apr 2018 Planned End Date changed from 31 Dec 2018 to 31 Oct 2019.